The present application relates to a putrescine-producing microorganism in which the activity of formate dehydrogenase is increased, and a method for producing putrescine using the same.

The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.

The invention relates to compositions and methods, including polynucleotide sequences, amino acid sequences, recombinant host cells and recombinant host cell cultures engineered to produce fatty acid derivative compositions comprising fatty acids, fatty alcohols, fatty aldehydes, fatty esters, alkanes, terminal olefins, internal olefins or ketones. The fatty acid derivative composition is produced extracellularly with a higher titer, yield or productivity than the corresponding wild type or non-engineered host cell.

The present invention relates to a recombinant microorganism capable of producing putrescine, in which the microorganism is modified to have enhanced NCgl2522 activity, thereby producing putrescine in a high yield, and a method for producing putrescine using the microorganism.

The present invention is directed to ILT7 binding molecules, e.g., anti-ILT7 antibodies, and methods for treating or preventing conditions and diseases associated with ILT7-expressing cells such as autoimmune diseases.

Disclosed are recombinant strain of a genus Corynebacterium capable of producing biliverdin IX-alpha (IXα) and a method of producing biliverdin IX-alpha using the same. The recombinant strain is capable of synthesizing biliverdin IX-alpha in an environmentally friendly manner using only glucose without the addition of any nitrogen source, thus replacing the synthesis of biliverdin IX-alpha through chemical treatment, which is a conventional synthetic method causing environmental pollution problems.

The invention provides compositions and methods for engineering E. coli or other host production bacterial strains to produce fucosylated oligosaccharides, and the use thereof in the prevention or treatment of infection.

The invention provides microorganisms genetically modified to co-overexpress a carbohydrate binding module and lysine decarboxylase polypeptides in a mesophilic host to enhance the production of lysine derivatives by the microorganism, method of generating such microorganism, and methods of producing lysine derivatives using the genetically modified microorganisms.

Disclosed herein are engineered cells and cell-free systems, compositions, and methods for conversion of isopentenols to isoprenoid precursors.

The present disclosure relates to a novel chitinolytic enzyme, particularly to a chitinolytic enzyme including an exo-β-N-acetylglucosaminidase (Clocel_3193) constituting a cellulosome derived from Clostridium cellulovorans as an active ingredient. The present disclosure allows utilization of chitin biomass which has not been used formerly as a raw material and allows environment-friendly production of N-acetylglucosamine. In addition, since the Clocel_3193 has a cell wall binding ability and degrading ability, the Clocel_3193 may be used in an antifungal composition.